No Data
No Data
Sh Pharma (02607): The exercise period for stock options is from July 8 to July 22.
Sh Pharma (02607) has announced the initial grant of stock options for its 2019 A-share stock option incentive plan.
Shanghai Pharmaceuticals Gets Nod to Register Ezetimibe Tablets
Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate for its ezetimibe tablets from China's National Medical Produ
Sh Pharma (601607.SH): Approval for production of Icotinib tablets obtained.
Sh Pharma (601607.SH) announced on July 3 that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd (referred to as "Changzhou Pharmaceutical Factory"), has received a Drug Registration Certificate (Certificate No.: 2024S01240) issued by the National Medical Products Administration for its pharmaceutical product, Ezetimibe Tablets. The product has been approved for production and is mainly used to treat symptoms such as primary hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (or plant sterolemia).
sh pharma (601607.SH): Approval granted for production of sitagliptin phosphate tablets.
Sh pharma (601607.SH) announced on July 2nd that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received the Drug Registration Certificate (Certificate No. 2024S01218, 2024S01219, 2024S01220) issued by National Medical Products Administration for its Siglitin phosphate tablets (referred to as "the pharmaceutical"), and has been approved for production. Siglitin phosphate tablets are mainly used to improve blood sugar control in patients with type 2 diabetes.
Sh Pharma: Clinical trial approval notice received for WST03 preparation.
Sh pharma (02607) announced that its wholly-owned subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd., has received the Drug Clinical Trial Approval Notice for WST03 Formulation (Capsule) (hereinafter referred to as "WST03 Formulation" or the project) issued by the State Drug Administration. The Phase I clinical trial will be launched in China in the near future. It is reported that WST03 is a microecological preparation for vaginal use, intended for the treatment of bacterial vaginosis (BV). Preclinical studies have shown that the WST03 formulation has the effect of effectively treating BV and preventing its recurrence.
An Intrinsic Calculation For Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Suggests It's 44% Undervalued
Key Insights The projected fair value for Shanghai Pharmaceuticals Holding is CN¥34.89 based on 2 Stage Free Cash Flow to Equity Shanghai Pharmaceuticals Holding's CN¥19.38 share price signals that
No Data